ArticleInfection and immunity2001
Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03115073 (A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001), which is not on this map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001
Who cites it
125 citing papers in PubMed, 248 citations in OpenAlex.
- Dual-Targeting, Hybrid Antifungal Agents Targeting Candida albicans-An Overview.Chemical biology & drug design · 2026Review
- Vascular Notch-Related Protein Expression in a Rat Model of Central Venous Catheter-AssociatedPathogens (Basel, Switzerland) · 2026Article
- Temperature-associated metabolic responses of Aspergillus cristatus revealed by untargeted LC-MS metabolomics.World journal of microbiology & biotechnology · 2026Article
- The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases.NPJ biofilms and microbiomes · 2026Review
- The role ofMicrobiology spectrum · 2026Article
- Temperature modulates infection-associated metabolic responses in bloom-forming freshwater diatoms.ISME communications · 2026Article
- Altered gut mycobiome and cross-kingdom microbial interactions in systemic lupus erythematosus.Journal of translational medicine · 2025Article
- Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure.Clinical and molecular hepatology · 2025Article
- Discovering a new paradigm: Gut microbiota as a central modulator of sexual health.World journal of gastrointestinal pathophysiology · 2025Review
- Exploring Oxylipins in Host-Microbe Interactions and Their Impact on Infection and Immunity.Current issues in molecular biology · 2025Review
- Microbial adaptive pathogenicity strategies to the host inflammatory environment.FEMS microbiology reviews · 2025Review
- Life stage impact on the human skin ecosystem: lipids and the microbial community.NPJ biofilms and microbiomes · 2025Article
- Gut mycobiome in cardiometabolic disease progression: current evidence and future directions.Frontiers in microbiology · 2025Review
- Host immune response against fungal biofilms.Current opinion in microbiology · 2024Review
- Macrophage fate: to kill or not to kill?Infection and immunity · 2024Review
- Gut mycobiome in metabolic diseases: Mechanisms and clinical implication.Biomedical journal · 2024Review
- Early-life ruminal microbiome-derived indole-3-carboxaldehyde and prostaglandin D2 are effective promoters of rumen development.Genome biology · 2024Article
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Can nonsteroidal anti-inflammatory drugs (NSAIDs) be repurposed for fungal infection?Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.Oxford open immunology · 2024Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Enhanced prostaglandin production during fungal infection could be an important factor in promoting fungal colonization and chronic infection. Host cells are one source of prostaglandins; however, another potential source of prostaglandins is the fungal pathogen itself. Our objective was to determine if the pathogenic yeasts Cryptococcus neoformans and Candida albicans produce prostaglandins and, if so, to begin to define the role of these bioactive lipids in yeast biology and disease pathogenesis. C. neoformans and C. albicans both secreted prostaglandins de novo or via conversion of exogenous arachidonic acid. Treatment with cyclooxygenase inhibitors dramatically reduced the viability of the yeast and the production of prostaglandins, suggesting that an essential cyclooxygenase like enzyme may be responsible for fungal prostaglandin production. A PGE series lipid was purified from both C. albicans and C. neoformans and was biologically active on both fungal and mammalian cells. Fungal PGE(x) and synthetic PGE(2) enhanced the yeast-to-hypha transition in C. albicans. Furthermore, in mammalian cells, fungal PGE(x) down-modulated chemokine production, tumor necrosis factor alpha production, and splenocyte proliferation while up-regulating interleukin 10 production. These are all activities previously documented for mammalian PGE(2). Thus, eicosanoids are produced by pathogenic fungi, are critical for growth of the fungi, and can modulate host immune functions. The discovery that pathogenic fungi produce and respond to immunomodulatory eicosanoids reveals a virulence mechanism that has potentially great implications for understanding the mechanisms of chronic fungal infection, immune deviation, and fungi as disease cofactors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.